Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Infusion Duration in RA
NCT01468077Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2011
- Primary completion
- Sep 2013
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 2 trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Started Nov 2011; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01468077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01468077.